

CJDQ443A12101 (Novartis)

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation.
This is the trial summary as assessed on clinicaltrials.gov on 17/11/2021.

Minor changes in the protocol may occur. You can check this on this direct link:
<https://clinicaltrials.gov/ct2/show/NCT04699188>

Trial Design:

Arm	Intervention
Experimental: Arm A	JDQ443 - KRAS G12C inhibitor
Experimental: Arm B	JDQ443 - KRAS G12C inhibitor TNO155 - SHP2 inhibitor
Experimental: Arm C	JDQ443 - KRAS G12C inhibitor Spartalizumab - Anti PD1 antibody
Experimental: Arm D	JDQ443 - KRAS G12C inhibitor TNO155 - SHP2 inhibitor Spartalizumab - Anti PD1 antibody

Inclusion criteria:

- Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors
- Prior treatment with a KRAS G12C inhibitor may be allowed for dose escalations of combinations

Exclusion criteria:

- Tumors harboring driver mutations that have approved therapies or tumors with known activating KRAS, NRAS, HRAS, BRAF or PTPN11 (SHP2) mutations, with exception of KRAS G12C mutations
- Active brain metastases
- Clinically significant cardiac disease or risk factors at screening